About StrideBio
StrideBio is a company based in Durham (United States) founded in 2015.. StrideBio has raised $98.2 million across 3 funding rounds from investors including ARE, Takeda Pharmaceuticals and Sarepta Therapeutics. The company has 109 employees as of December 31, 2022. StrideBio offers products and services including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline. StrideBio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Durham, United States
- Employees 109 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Stridebio, Inc.
-
Annual Revenue
$00as on Jun 05, 2017
-
Net Profit
-
EBITDA
-
Total Equity Funding
$98.2 M (USD)
in 3 rounds
-
Latest Funding Round
$81.5 M (USD), Series B
Mar 16, 2021
-
Investors
ARE
& 11 more
-
Employee Count
109
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of StrideBio
StrideBio offers a comprehensive portfolio of products and services, including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing advanced gene therapies.
Service for producing AAV vectors used in gene therapy.
Pipeline of gene therapies targeting life-threatening diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of StrideBio
StrideBio has successfully raised a total of $98.2M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $81.5 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $81.5M
-
First Round
First Round
(05 Jun 2017)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - StrideBio | Valuation | Novo Holdings , Northpond Ventures | |
| Jun, 2018 | Amount | Series A - StrideBio | Valuation | Hatteras Venture Partners | |
| Jun, 2017 | Amount | Seed - StrideBio | Valuation | Hatteras Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in StrideBio
StrideBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Takeda Pharmaceuticals and Sarepta Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by StrideBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - StrideBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stridebio Comparisons
Competitors of StrideBio
StrideBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stridebio
Frequently Asked Questions about StrideBio
When was StrideBio founded?
StrideBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is StrideBio located?
StrideBio is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is StrideBio a funded company?
StrideBio is a funded company, having raised a total of $98.2M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 05, 2017.
How many employees does StrideBio have?
As of Dec 31, 2022, the latest employee count at StrideBio is 109.
What does StrideBio do?
Founded in 2015 and headquartered in Durham, United States, AAV-based gene therapies for rare diseases are developed within the biotechnology sector. Therapies are targeted at conditions including Friedreichs ataxia, Niemann-Pick disease type C, Angelman syndrome, Dravet syndrome, and Rett syndrome. Operations rely on a structure-inspired adeno-associated virus vector engineering platform to advance treatment options.
Who are the top competitors of StrideBio?
StrideBio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does StrideBio offer?
StrideBio offers STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline.
Who are StrideBio's investors?
StrideBio has 12 investors. Key investors include ARE, Takeda Pharmaceuticals, Sarepta Therapeutics, Novo Holdings, and Pontifax Venture Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.